300653 正海生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)3.7799.26914.66021.06322.472
总资产报酬率 ROA (%)3.4088.38913.23918.71519.358
投入资产回报率 ROIC (%)3.7069.06414.17920.22621.433

边际利润分析
销售毛利率 (%)82.37285.87787.64389.90188.723
营业利润率 (%)22.96824.50441.98752.83948.952
息税前利润/营业总收入 (%)22.94424.10541.80952.65548.753
净利润/营业总收入 (%)20.84622.63237.06846.16442.804

收益指标分析
经营活动净收益/利润总额(%)80.43583.28683.69487.54393.008
价值变动净收益/利润总额(%)18.69715.36911.84711.5693.393
营业外收支净额/利润总额(%)0.142-1.250-0.085-0.0800.017

偿债能力分析
流动比率 (X)8.3798.6048.8228.5626.723
速动比率 (X)7.9968.2578.3868.1546.337
资产负债率 (%)9.9699.6639.31810.03612.341
带息债务/全部投入资本 (%)0.9840.6031.5572.2052.366
股东权益/带息债务 (%)9,939.29416,292.8306,249.2124,362.9964,050.358
股东权益/负债合计 (%)903.069934.921973.162896.437710.287
利息保障倍数 (X)-402.014-250.962-294.261-369.890-235.612

营运能力分析
应收账款周转天数 (天)65.64752.23549.36342.09337.683
存货周转天数 (天)199.716226.576288.338333.560275.121